CVS Health Corp vs Otis Worldwide Corp — how do they compare? CVS Health Corp trades at $86.37 (market cap $112.29B), while Otis Worldwide Corp trades at $65.98 (market cap $25.17B). The key difference: CVS Health Corp is far larger — about 4.5× Otis Worldwide Corp's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Otis Worldwide Corp for 66 Days on average.
| CVS | OTIS | |
|---|---|---|
Market Cap | $112.29B | $25.17B |
Volume | 7,763,676 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $110.60 | $93.62 |
52-Week Low | $70.08 | $64.05 |
Typical Hold Time | 83 Days | 66 Days |
Enterprise Value | $174.64B | $33.20B |
Dividend Yield | 3.03% | 2.66% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.
CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.
Otis Worldwide trades at $66.14, up 0.61% today but near its 52-week low, with technical indicators showing bearish momentum. The company reported mixed Q2 2026 results, missing EPS estimates while maintaining strong service revenue growth. Recent CEO succession news and China market challenges create uncertainty, though analyst consensus remains positive with a $87 price target representing 31% upside potential.
The stock presents a value opportunity with reasonable P/E of 16.99 and P/S of 1.73, but faces margin pressure and execution risks. Service segment growth and modernization backlog provide stability, while weak equipment demand and China exposure remain headwinds. Institutional ownership shows mixed signals with recent buying and selling activity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →